^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tilsotolimod (IMO-2125)

    i
    Associations
    News

    Trials

    Company:
    Aceragen
    Drug class:
    TLR9 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma (ILLUMINATE 204) (NCT02644967)
    Phase 2
    Idera Pharmaceuticals, Inc.
    Completed
    Last update posted :
    08/03/2022
    Initiation :
    12/01/2015
    Primary completion :
    02/01/2020
    Completion :
    05/01/2021
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • tilsotolimod (IMO-2125)